HW
HZNP

Hancock Whitney’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Hancock Whitney’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,144
Closed -$331K – 691
2022
Q1 		$331K Buy
3,144
+63
+2% +$6.14K 0.01% 573
2021
Q4 		$332K Buy
3,081
+127
+4% +$13.9K 0.01% 568
2021
Q3 		$324K Sell
2,954
-6,382
-68% -$663K 0.01% 555
2021
Q2 		$874K Sell
9,336
-19
-0.2% -$1.75K 0.03% 432
2021
Q1 		$861K Sell
9,355
-504
-5% -$42.5K 0.03% 428
2020
Q4 		$721K Sell
9,859
-6,721
-41% -$500K 0.02% 443
2020
Q3 		$1.29M Sell
16,580
-4,645
-22% -$320K 0.05% 328
2020
Q2 		$1.18M Sell
21,225
-24,958
-54% -$1.07M 0.05% 340
2020
Q1 		$1.37M Sell
46,183
-850
-2% -$28.8K 0.05% 315
2019
Q4 		$1.7M Sell
47,033
-7,870
-14% -$241K 0.05% 336
2019
Q3 		$1.5M Sell
54,903
-6,319
-10% -$163K 0.05% 357
2019
Q2 		$1.47M Buy
+61,222
New +$1.55M 0.05% 370

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Hancock Whitney's HZNP Position: Q2 2022 in Review

Hancock Whitney sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 3,144 shares — an estimated $331K sold.

Hancock Whitney first reported a position in HZNP in Q2 2019 and held it in 12 quarters. The position peaked at $1.7M in Q4 2019. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

  • Hancock Whitney reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • Hancock Whitney sold 3,144 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $331K.
  • Hancock Whitney first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019 and held it in 12 quarters.
  • Hancock Whitney's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.7M in Q4 2019.
  • 616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Hancock Whitney's 13F filing for Q2 2022, filed 8 Aug 2022.